Premium
Serotonergic and non‐serotonergic targets in the pharmacotherapy of visceral hypersensitivity
Author(s) -
Bueno L.,
De Ponti F.,
Fried M.,
Kullakublick G. A.,
Kwiatek M. A.,
Pohl D.,
Quigley E. M. M.,
Tack J.,
Talley N. J.
Publication year - 2007
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/j.1365-2982.2006.00876.x
Subject(s) - serotonergic , medicine , pharmacogenomics , pharmacotherapy , pathogenesis , mechanism (biology) , bioinformatics , pharmacology , immunology , serotonin , biology , receptor , philosophy , epistemology
Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.